Literature DB >> 28829055

A further strategy to combat the high price of anticancer drugs.

Vinay Prasad1, Kevin De Jesús2, Sham Mailankody3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28829055     DOI： 10.1038/nrclinonc.2017.137

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

1.  The accelerated approval of oncologic drugs: lessons from ponatinib.

Authors:  Vinay Prasad; Sham Mailankody
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

2.  A further strategy to combat the high price of anticancer drugs.

Authors:  Peter J Gilbar
Journal:  Nat Rev Clin Oncol       Date:  2017-08-22       Impact factor: 66.675

Review 3.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

4.  Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.

Authors:  Andrew Hill; Dzintars Gotham; Joseph Fortunak; Jonathan Meldrum; Isabelle Erbacher; Manuel Martin; Haitham Shoman; Jacob Levi; William G Powderly; Mark Bower
Journal:  BMJ Open       Date:  2016-01-27       Impact factor: 2.692
  4 in total
  1 in total

1.  "Real world survey" of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients.

Authors:  Ji-Bing Chen; Xiao-Feng Kong; You-Yong Lv; Shu-Cun Qin; Xue-Jun Sun; Feng Mu; Tian-Yu Lu; Ke-Cheng Xu
Journal:  Med Gas Res       Date:  2019 Jul-Sep
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.